Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Amylyx Pharmaceuticals, Inc. - Common Stock
SCP & CO Healthcare Acquisition Company - Class A Common Stock
Tempus AI, Inc. - Class A Common Stock
Edit Watchlist
Top Indices
NASDAQ Composite
Standard & Poors 500
My Portfolio
Articles published by Tempus AI, Inc.
< Previous
1
2
3
4
Next >
Tempus to Present Six Abstracts Accepted at the 2026 Connective Tissue Oncology Society Annual Meeting
November 11, 2026
From
Tempus AI, Inc.
Via
Business Wire
Tickers
TEM
Tempus Reports Third Quarter 2026 Results
November 02, 2026
From
Tempus AI, Inc.
Via
Business Wire
Tickers
TEM
Tempus Receives IVDR Certification for xR RNA Sequencing for Solid Tumor Profiling
October 26, 2026
From
Tempus AI, Inc.
Via
Business Wire
Tickers
TEM
Tempus Expands Strategic Collaboration with Bristol Myers Squibb
October 23, 2026
From
Tempus AI, Inc.
Via
Business Wire
Tickers
TEM
Tempus Presents Data Demonstrating AI-Enabled Pre-Screening Can Help Identify Patients for Biomarker Testing in NSCLC
October 19, 2026
From
Tempus AI, Inc.
Via
Business Wire
Tickers
TEM
Tempus to Report Third Quarter 2026 Financial Results on November 2
October 15, 2026
From
Tempus AI, Inc.
Via
Business Wire
Tickers
TEM
Tempus Announces 13 Abstracts Accepted for Presentation at the European Society for Medical Oncology Congress 2026
October 01, 2026
From
Tempus AI, Inc.
Via
Business Wire
Tickers
TEM
Tempus Receives FDA Clearance for its ECG-MR AI Product Designed to Identify Undiagnosed Mitral Regurgitation
September 28, 2026
From
Tempus AI, Inc.
Via
Business Wire
Tickers
TEM
Tempus and Recursion Extend Existing Data License Agreement and Enter New License Agreement for Recursion’s RNA Foundation Model
September 21, 2026
From
Tempus AI, Inc.
Via
Business Wire
Tickers
TEM
Tempus Launches Effort to Build the Largest Multimodal Whole-Genome Dataset to Advance AI-Driven Healthcare Innovation
September 11, 2026
From
Tempus AI, Inc.
Via
Business Wire
Tickers
TEM
Tempus Secures Up to $9.5 Million in ARPA-H ADVOCATE Funding to Deploy First Autonomous AI in Cardiology
September 09, 2026
From
Tempus AI, Inc.
Via
Business Wire
Tickers
TEM
Tempus to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
September 04, 2026
From
Tempus AI, Inc.
Via
Business Wire
Tickers
TEM
Tempus Receives FDA Clearance for its AI Product Intended to Detect Signs of Pulmonary Hypertension From Standard ECGs
August 24, 2026
From
Tempus AI, Inc.
Via
Business Wire
Tickers
TEM
Tempus Study Published in Nature Medicine Demonstrates Best-in-Class Performance of PRISM2 Across Diagnostic and Prognostic Applications
August 04, 2026
From
Tempus AI, Inc.
Via
Business Wire
Tickers
TEM
Tempus Reports Second Quarter 2026 Results
July 30, 2026
From
Tempus AI, Inc.
Via
Business Wire
Tickers
TEM
Tempus to Report Second Quarter 2026 Financial Results on July 30
July 09, 2026
From
Tempus AI, Inc.
Via
Business Wire
Tickers
TEM
Tempus Announces Research Collaboration with Angiosarcoma Awareness, Inc. to Uncover Insights on Rare Cancers
June 25, 2026
From
Tempus AI, Inc.
Via
Business Wire
Tickers
TEM
Tempus Announces Multi-Center Validation of AI-Enabled ECG Model for Predicting Atrial Fibrillation Risk Published in Heart Rhythm
June 11, 2026
From
Tempus AI, Inc.
Via
Business Wire
Tickers
TEM
Tempus to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
June 05, 2026
From
Tempus AI, Inc.
Via
Business Wire
Tickers
TEM
Tempus Launches Open-Source Digital Pathology Consortium, Names Yale New Haven Health and Leading Cancer Center as Founding Members
June 03, 2026
From
Tempus AI, Inc.
Via
Business Wire
Tickers
TEM
Tempus Announces the Upcoming Clinical Availability of Its First Whole-Genome Sequencing Assay, xH
June 01, 2026
From
Tempus AI, Inc.
Via
Business Wire
Tickers
TEM
Tempus Unveils the Next-Generation of Lens, Expanding its Agentic AI Platform for Oncology Drug Development
May 31, 2026
From
Tempus AI, Inc.
Via
Business Wire
Tickers
TEM
Tempus Launches the PRECISION Challenge, a National Program Opening Its Foundation Model Work to the Broader Research Community
May 30, 2026
From
Tempus AI, Inc.
Via
Business Wire
Tickers
TEM
Tempus Introduces ‘Preview’: Bridging the Critical Time Gap Between Diagnostic Order and Definitive Results
May 30, 2026
From
Tempus AI, Inc.
Via
Business Wire
Tickers
TEM
Tempus Announces Initial Results from its Multimodal Foundation Model Efforts for Novel and Scalable Insight Generation in Oncology
May 29, 2026
From
Tempus AI, Inc.
Via
Business Wire
Tickers
TEM
Tempus Receives FDA Approval for Tumor Only xT CDx, Enabling Migration of its Entire DNA Solid Tumor Portfolio
May 29, 2026
From
Tempus AI, Inc.
Via
Business Wire
Tickers
TEM
Tempus Expands Next Platform to Deliver Real-Time Clinical Intelligence and Close Critical Care Gaps Across Oncology
May 28, 2026
From
Tempus AI, Inc.
Via
Business Wire
Tickers
TEM
Tempus Upgrades Its Smart Physician Platform, Hub, with Next-Generation Agentic AI Architecture to Streamline Clinical Workflows
May 27, 2026
From
Tempus AI, Inc.
Via
Business Wire
Tickers
TEM
Tempus Announces 37 Abstracts Accepted for Presentation at the 2026 American Society of Clinical Oncology Annual Meeting
May 26, 2026
From
Tempus AI, Inc.
Via
Business Wire
Tickers
TEM
Tempus Launches ArteraAI Prostate Test for Metastatic Patients, Marking the First Prostate Digital Pathology Algorithm in the Tempus Ecosystem Available for Clinical Use
May 21, 2026
From
Tempus AI, Inc.
Via
Business Wire
Tickers
TEM
< Previous
1
2
3
4
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.